The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Nektar Therapeutics has announced that it will be regaining the full rights to rezpegaldesleukin (REZPEG; NKTR-358) from Eli Lilly (NYSE: LLY) which concludes the two companies’ collaboration that begun in 2017. 28 April 2023
Eli Lilly’s tirzepatide moved a step closer to seizing a share of the obesity market on Thursday, when the US drugmaker’s shares were up by more than 2% in early trading. 27 April 2023
When it comes to getting a novel foreign-made treatment into China as quickly as possible, companies should also look into the local policies in some high-profile special zones. 27 April 2023
US pharma major AbbVie today reported earnings for first quarter of 2023 that were lower than the same period of last year but came in line with the Wall Street estimates. 27 April 2023
Swedish Orphan Biovitrum, also known as Sobi, today released financial results for the first quarter of 2023, showing that total revenues were up 6% year-on-year at 5,239 million Swedish kronor ($508.6 million), but down 2% at constant exchange rates (CER). 27 April 2023
A fall in sales of the COVID-19 treatment Lagevrio (molnupiravir) led revenue at Merck & Co to fall by 9% to $14.49 billion in the first quarter of 2023. 27 April 2023
UK pharma major AstraZeneca this morning reported first-quarter 2023 financial results, with total revenues of $10.879 billion, a decline of 4% (1% increase at constant exchange rates) impacted by lower sales of COVID-19 medicines. 27 April 2023
Cambridge, USA-based Orbital Therapeutics, which debuted last September with the vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible, has now announced the successful closing of a $270 million Series A financing. 27 April 2023
Shares of US drugmaker Vertex Pharmaceuticals closed down 2.6% at $323.30 yesterday, despite the firm announcing that the US Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor). 27 April 2023
German generics drugmaker STADA Arzneimittel and Sweden’s Xbrane Biopharma are working together on a supply agreement for Ximluci (ranibizumab). 27 April 2023
Outperforming many analysts’ expectations, French drugmaker Sanofi has posted revenues of 10.2 billion euros ($11.3 billion) for the first quarter 2023. 27 April 2023
In a first, more adult patients living with certain forms of blood cancer will now be able to access CAR T-cell therapy on the UK’s National Health Service (NHS). 27 April 2023
The US Food and |Drug Administration (FDA) has released briefing documents for the April 28, 2023, Advisory Committee Meeting (AdCom) discussing the supplemental new drug application (sNDA) for UK AstraZeneca’s Lynparza (olaparib) in first-line (1L) metastatic castration-resistant prostate cancer (mCRPC). 27 April 2023
A new antibody therapy targeting coronavirus has “demonstrated benefit” in a Phase III trial, according to a statement from SAB Biotherapeutics, while markets reacted negatively to the top-line results. 27 April 2023
The International Council for Harmonization (ICH) has initiated the process for a new guideline on bioequivalence requirements for the approval of medicines, which is an important milestone for global convergence. 26 April 2023
With another set of strong data under its belt, Swiss pharma giant Novartis is now looking to filing regulatory applications for its investigational oral monotherapy iptacopan. 26 April 2023